Inhaled antibiotic shows promise for ventilator lung infections
NCT ID NCT07369336
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding an inhaled antibiotic (amikacin) to standard treatment helps ICU patients recover faster from ventilator-associated pneumonia. Researchers tracked how quickly the infection cleared, how long patients needed the ventilator, and any side effects. The trial included 90 adults aged 18-80 who were on ventilators and diagnosed with VAP.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VENTILATOR-ASSOCIATED PNEUMONIA (VAP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lahore General Hospital
Lahore, Punjab Province, 54000, Pakistan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Lung germ shifts may predict pneumonia in brain surgery ICU patients
- Can a simple inhaled antibiotic stop ventilator pneumonia?
- Elderly ICU Patients' immune paralysis linked to pneumonia risk
- New monitoring method may cut pneumonia risk in ventilated patients
- Nurse training aims to cut ICU infections in developing nations
- New test aims to get the right antibiotics to ICU pneumonia patients faster